GlassScriptPhysician profile
Shilesh Iyer
NPI 1841351277
$9,219.50
in general payments reported to CMS, 2019-2025
31 companies · $653 in 2025
The $653 reported for 2025 was more than what 83% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,161 · 2020: $449 · 2021: $691 · 2022: $636 · 2023: $837 · 2024: $793 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,283.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $4,432.34 | 2019 | |
| Abbvie INC. | $870.18 | 2019-2025 | |
| Galderma Laboratories, L.P. | $575.74 | 2019-2025 | Dysport |
| Novartis Pharmaceuticals Corporation | $387.10 | 2019-2024 | |
| Amgen INC. | $351.17 | 2021-2024 | Otezla |
| Regeneron Healthcare Solutions, INC. | $283.62 | 2019-2025 | Dupixent |
| Pfizer INC. | $272.41 | 2019-2025 | |
| Dermavant Sciences, INC. | $271.33 | 2023-2024 | Vtama |
| Genzyme Corporation | $240.02 | 2022-2025 | |
| Incyte Corporation | $215.14 | 2022-2025 | Opzelura |
| Janssen Biotech, INC. | $212.83 | 2019-2023 | Tremfya, Remicade, Simponi |
| Lilly USA, LLC | $173.44 | 2020-2025 | Ebglyss, Olumiant |
| Leo Pharma INC. | $107.95 | 2021-2025 | Adbry |
| Sandoz INC. | $98.31 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.54 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $89.03 | 2023-2024 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $86.40 | 2023-2025 | Zoryve |
| Genentech USA, INC. | $74.39 | 2021 | |
| Ucb, INC. | $57.54 | 2024-2025 | Bimzelx |
| Journey Medical Corporation | $46.13 | 2020-2022 | |
| Botanix Sb INC | $45.80 | 2025 | Sofdra |
| Biofrontera INC. | $38.89 | 2021-2022 | |
| Helsinn Therapeutics (U.S.), INC. | $38.86 | 2022-2024 | Valchlor |
| Blueprint Medicines Corporation | $26.69 | 2024 | Ayvakit |
| Mayne Pharma Commercial LLC | $22.78 | 2019 | |
| Celgene Corporation | $22.21 | 2019 | |
| Sun Pharmaceutical Industries INC. | $21.81 | 2024 | |
| Paratek Pharmaceuticals, INC. | $20.37 | 2024 | Nuzyra |
| Almirall LLC | $19.43 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.33 | 2021 | |
| Strata Skin Sciences, INC. | $13.72 | 2024 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilesh Iyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.